Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

How do I Recognize and Treat the VEXAS Syndrome?

Cleveland Clinic Rheumatology

P. Grayson

Pulmonary Embolism: Role of Catheter-Based Interventions

Baylor College of Medicine

P. Loyalka

ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

2024 Updates on Emerging & Current Treatment of Multiple Myeloma

Indy Hematology Review

K. Anderson

Spine Ablation in 2023: Indications, Goals, Guidelines, Evidence, an…

Jason Levy

ASH 2023 Summary: "The Best of Myeloma - Highlights & Key Takeaways"

Insights from 2023 ASH Annual Meeting

H. Hashmi

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

SOHO Brazil 2024

A. Zelenetz

ASCO® 2024 Summary: "The Best of Myeloma - Review of the Top 5 Abstr…

2024 ASCO® Annual Meeting Insights Hub

H. Hashmi

Thrombophilia Screening: Best Practices and Who Should Be Tested

COR2ED The Heart of Medical Education

S. Middeldorp, J. Connors

Advances in Multiple Myeloma 2024: From Bench to Bedside

Dana-Farber Cancer Institute

K. Anderson

R/R DLBCL: Are Bispecific Antibodies Superior to CAR-T?

Moffitt Cancer Center

J. Chavez

Multiple Myeloma: A Journey From Pharaoh's Times to 2024

Houston Methodist

S. Ganguly

Managing Newly Diagnosed MM in 2024

Indy Hematology Review

S. Usmani

ASH 2023 Insights: "Highlights in 1L MM - Quadruplet Therapies on a …

Insights from 2023 ASH Annual Meeting

A. Jakubowiak

Multiple Myeloma: Not as Simple as "CRAB" Anymore

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

R. Banerjee

Will CAR-Ts and Bispecifics Replace HSCT in Myeloma?

MyCancerHaven

R. Vij, S. Al Hadidi

New Updates in Frontline DLBCL

Scripps Health

L. Nastoupil

When to Consider Bispecific and CAR-T Therapy in MM

SOHO Brazil 2024

N. S. Raje